Out of 8 analysts covering Heron Therapeutics (NASDAQ:HRTX), 8 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Heron Therapeutics was the topic in 10 analyst reports since August 3, 2015 according to StockzIntelligence Inc. Below is a list of Heron Therapeutics Inc (NASDAQ:HRTX) latest ratings and price target changes.
10/12/2015 Broker: Lake Street Rating: Buy New Target: $45 Initiate
The stock increased 21.11% or $3.43 during the last trading session, hitting $19.68. About 1.15M shares traded hands or 61.48% up from the average. Heron Therapeutics Inc (NASDAQ:HRTX) has declined 43.85% since August 21, 2015 and is downtrending. It has underperformed by 43.92% the S&P500.
Heron Therapeutics, Inc. is a biotechnology company. The company has a market cap of $709.55 million. The Firm uses its technology to develop products to address unmet medical needs. It currently has negative earnings. The Company’s Biochronomer polymer drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals.
Heron Therapeutics Inc - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.